04:20 , Dec 8, 2017 |  BC Week In Review  |  Company News

J&J opts in for Idorsia's hypertension candidate

Idorsia Ltd. (SIX:IDIA) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577) and its derivatives. Idorsia will be responsible for Phase III development and...
22:27 , Dec 4, 2017 |  BC Extra  |  Company News

J&J opts in for Idorsia's hypertension candidate

Idorsia Ltd. (SIX:IDIA) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577) and its derivatives. Idorsia will be responsible for Phase III development and...
19:33 , Jun 16, 2017 |  BC Extra  |  Financial News

Actelion spinout Idorsia rises in first trading day

Idorsia Ltd. (SIX:IDIA) gained CHF3.65 (37%) to CHF13.65 in its first day of trading on Friday. The closing price valued the company at CHF1.5 billion ($1.5 billion). Idorsia was spun out of Actelion Ltd. (SIX:ATLN),...
23:39 , Jun 9, 2017 |  BC Extra  |  Financial News

Actelion spinout Idorsia to list next week

On June 16, shares of Idorsia Ltd. (Allschwil, Switzerland) are to begin trading on the SIX Swiss Exchange. Idorsia will house the drug discovery and early clinical pipeline businesses of Actelion Ltd. (SIX:ATLN), which Johnson...
19:40 , May 26, 2017 |  BC Week In Review  |  Clinical News

Actelion's endothelin receptor antagonist reduces blood pressure in Phase II

Actelion Ltd. (SIX:ATLN) said ACT-132577 led to "significant dose-dependent" reductions in diastolic and systolic blood pressure in a double-blind Phase II trial to treat essential hypertension. In 410 evaluable patients in the per protocol (PP)...
20:39 , May 22, 2017 |  BC Extra  |  Clinical News

Actelion reports hypertension data amid Idorsia spinout

In a pipeline update outlining candidates it plans to spin out into newco Idorsia Ltd. , Actelion Ltd. (SIX:ATLN) said ACT-132577 led to "statistically significant dose-dependent" reductions in both diastolic and systolic blood pressure in...
03:07 , Feb 4, 2017 |  BioCentury  |  Strategy

Actelion, take two

After surviving takeover attempts, an investor mutiny and a make-or-break gamble on Opsumit macitentan, Actelion Ltd. co-founder and CEO Jean-Paul Clozel finally took a deal management couldn’t refuse. Johnson & Johnson ’s proposed $30 billion...
23:27 , Jan 27, 2017 |  BC Week In Review  |  Company News

J&J, Actelion deal

Johnson & Johnson will acquire Actelion for $280 per share in cash, or about $30 billion. Based on current exchange rates, the price is a 23% premium to Actelion's closing price of CHF227.40 on Jan....
00:44 , Jan 27, 2017 |  BC Extra  |  Company News

J&J acquiring Actelion, spinning out newco

Johnson & Johnson (NYSE:JNJ) will acquire Actelion Ltd. (SIX:ATLN) for $280 per share in cash, or about $30 billion. Based on current exchange rates, the price is a 23% premium to Actelion's closing price Wednesday...